ANI Pharmaceuticals Inc.
04/07/2026 | Press release | Distributed by Public on 04/07/2026 14:21
Change in Certifying Accountants (Form 8-K)
| Item 4.01 | Changes in Registrant's Certifying Accountant. |
(a) Dismissal of Independent Registered Public Accounting Firm
On April 1, 2026, ANI Pharmaceuticals, Inc. (the "Company") notified EisnerAmper LLP ("EisnerAmper") that EisnerAmper would be dismissed as the Company's independent registered public accounting firm. The Audit and Finance Committee of the Board of Directors of the Company (the "Audit Committee") approved the decision to dismiss EisnerAmper, which became effective on April 1, 2026.
The reports of EisnerAmper on the Company's financial statements as of and for the fiscal years ended December 31, 2025 and 2024 did not contain any adverse opinion or disclaimer of opinion, nor were such reports qualified or modified as to uncertainty, audit scope, or accounting principles.
During the fiscal years ended December 31, 2025 and 2024, and through April 1, 2026, there were (i) no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) with EisnerAmper on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of EisnerAmper, would have caused EisnerAmper to make reference thereto in their reports, and (ii) no "reportable events" requiring disclosure pursuant to Item 304(a)(1)(v) of Regulation S-K.
The Company provided EisnerAmper with a copy of this Current Report on Form 8-K prior to its filing with the Securities and Exchange Commission ("SEC") and requested that EisnerAmper furnish it with a letter addressed to the SEC stating whether or not it agrees with the above statements in this Item 4.01(a). A copy of EisnerAmper's letter, dated April 7, 2026, is filed as Exhibit 16.1 to this Current Report on Form 8-K.
(b) Appointment of New Independent Registered Public Accounting Firm
On April 1, 2026, the Audit Committee approved the appointment of Ernst & Young LLP ("EY"), effective April 1, 2026, as the Company's new independent registered public accounting firm for the fiscal year ended December 31, 2026. During the fiscal years ended December 31, 2025 and 2024 and the subsequent interim period through April 1, 2026, neither the Company nor anyone acting on its behalf consulted with EY regarding any of the matters referred to in Item 304(a)(2)(i) or (ii) of Regulation S-K.
ANI Pharmaceuticals Inc. published this content on April 07, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 07, 2026 at 20:21 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]